drugset
drugset / Trial / NCT05905926

Safety Study of Tenapanor for the Treatment of Pediatric Patients (6 to Less Than 18 Years Old) With IBS-C

NCT05905926 ↗

Phase 3 Enrolling by invitation 150 enrolled Ardelyx
NaSingle-groupOpen-labelHealth-services research

Summary

Open-label long-term safety study of tenapanor in pediatric patients with IBS-C.

Timeline

Start
2023-02-17
Primary completion
2031-07
Completion
2031-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Tenapanor Small molecule 25 mg —
Subject Tenapanor Small molecule 50 mg —

Indications

irritable bowel syndrome